Complex Generic Mid-Cycle Meetings: US FDA Suggests Taking The Date Offered

 
• By Derrick Gingery
  
Woman uses an inhaler during an asthma attack, close-up
The US FDA does not want complex generic sponsors to delay mid-cycle meetings if possible, because it could render them less productive.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Generics

More from Biosimilars & Generics